Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ebronucimab in Primary Hypercholesterolemia and Mixed Hyperlipidemia
NCT05255458Phase 3Completed
- Sponsor
- Akeso, Inc.
- Start
- Nov 2021
- Primary completion
- Jan 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ebronucimab in hypercholesterolemia, mixed hyperlipidemia, sponsored by Akeso, Inc.. Started Nov 2021; status: completed.
02
Drugs
ebronucimab
03
Conditions
hypercholesterolemiamixed hyperlipidemia
Beyond the preview
Go deeper on NCT05255458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05255458.